Dabigatranilla

Dabigatran itself is a subject of the dabigatran article, but "dabigatranilla" is a disapproved new chemical entity proposed as a prodrug of dabigatran.

Dabigatranilla, also known as dabigatran etexilate, is a once-daily oral anticoagulant used to prevent and treat thromboembolic events such as deep vein thrombosis and pulmonary embolism, and to prevent stroke in people with atrial fibrillation. It works by inhibiting the activity of thrombin, an enzyme that plays a key role in blood clot formation.

The development of dabigatranilla was initiated by Boehringer Ingelheim in the early 2000s, and it was first approved for use in Europe in 2008. Since then, it has been approved in many other countries, including the United States, Canada, and Australia. Dabigatranilla has been shown to be effective in reducing the risk of thromboembolic events in various clinical trials, and it has a relatively favorable safety profile compared to other anticoagulants.

Dabigatranilla is metabolized in the liver and excreted primarily in the urine. It has a half-life of around 12-17 hours, which allows for once-daily dosing. The recommended dose of dabigatranilla is 150 milligrams per day, but a reduced dose of 75 milligrams per day may be used for certain patients, such as those with kidney impairment or those taking other medications that interact with dabigatranilla.

Overall, dabigatranilla is an important medication for the prevention and treatment of thromboembolic events, and it is a valuable addition to the treatment options available for patients at risk of these conditions.